OraSure Technologies (OSUR) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $39.9 million, down 55% year-over-year, with core revenue declining 1% and COVID-19 revenue dropping 96% due to the end of major government contracts.

• Strong international performance in HIV diagnostics drove a 13% year-over-year increase in diagnostic product sales.

• The company is exiting its risk assessment and molecular services businesses by year-end 2024, focusing on core diagnostics and sample management.

• Initial international orders received for the OraQuick HCV self-test after WHO pre-qualification, with expansion into blood proteomics sample management planned for 2025.

• Operating loss for Q3 2024 was $6.0 million, compared to operating income of $10.9 million in Q3 2023.

Financial highlights

• Q3 total revenue was $39.9 million; core revenue (excluding COVID-19 and exited molecular services) was $37.8 million, down 1% year-over-year but would have grown 1% excluding risk assessment business.

• Diagnostic products generated $22 million in Q3, up 13% year-over-year, mainly driven by international HIV sales.

• Sample management revenue was $12.8 million, down 16% year-over-year but up sequentially for the second quarter in a row.

• COVID-19 products contributed $2.2 million, down 96% year-over-year, but above expectations due to late-quarter deliveries.

• GAAP gross margin was 42.8%; non-GAAP gross margin was 43.3%.

• Q3 net loss was $4.5 million (EPS: $(0.06)); non-GAAP EPS was $(0.01).

• Operating cash flow for Q3 was $12.7 million; cash and equivalents at quarter-end were $279 million with zero debt.

Outlook and guidance

• Q4 total revenue guidance: $36–$38 million; core revenue: $35–$37 million, including $1–$2 million from risk assessment testing as the business winds down.

• COVID-19 product revenue in Q4 expected at approximately $1 million.

• Gross margin in Q4 expected to be consistent with Q3, with long-term targets in the 50% range as operational efficiencies are realized.

• Moderate core growth anticipated in 2025, driven by new product launches and partnerships, with more details to be provided in February.

• Existing cash and cash equivalents are expected to be sufficient to fund operations and capital expenditures for at least the next twelve months.